The Assessment of Prednisone in Remission Trial (TAPIR)
CURRENTLY ENROLLING: YES
This study is comparing two doses of predniseon to treat patients with granulomatosis with polyangiitis who are in remission. The two doses are i) a low-dose of prednisone (5 mg per day) and ii) no prednisone (0 mg per day).
YES. The medication you need to take to participate in the study is prednisone.
Where patients with granulomatosis with polyangiitis (GPA) do just as well on no prednisone verses low-dose of prednisone once the patient is in remission.
Participants must have a confirmed diagnosis of GPA, be currently in remission, have needed to take 20 mg or more of prednisone each day at some point in the last 12 months, and is currently taking a dose of prednisone between 5 and 10 mg daily.
Up to 6 months
The TAPIR trial will randomize the participant to reduce their prednisone dose to either 5 mg or 0 mg a day and will be asked to keep a daily diary monitoring the prednisone dose. The participant will be asked to return to the hospital in 3 months and in 6 months, where they will have a physical exam, fill out a feedback form about their life, and bring the prednisone dose daily diary to review with the physician.
Thank you for your interest! If you wish to learn more and sign up for the study, please contact:
ALISON KEENAN
rheumatologyresearch@uphs.upenn.edu
215-614-4417